Lifescient recognizes that the COVID19 virus attacks the lungs via the nasal mucosa, causing inflammation in the lung and upper respiratory damage. Therefore, in response to the COVID19 global pandemic, we are repurposing a veterinary off-patent generic drug that has demonstrated antiviral activity against SARS-CoV-2 virus, the causative pathogen in COVID19.
Lifescient has filed a provisional patent for targeted delivery of ivermectin in combination with other off-patent generic drugs. The patent covers compositions and methods of treatment to manage symptoms associated with acute lung injury (ALI), in particular ALI caused by viral respiratory infections, including ALI caused by infection with coronavirus, notably infection with SARS-CoV‑2, causative pathogen for COVID19. The described compositions and methods provide a novel approach for the treatment of SARS-CoV-2 (COVID19) symptoms and pathology.
Since the drug is generic and freely available from multiple vendors, potential manufacturing and supply chain challenges are avoided and market demand can be met by making available a highly affordable drug for people worldwide.
In addition, Lifescient is currently developing a delivery platform that can be repurposed for other agents that are in clinical testing to treat COVID19. We believe our delivery platform, when applied to other treatments in development, will deliver the drug in a targeted fashion to the lungs, thereby maximizing the chances of developing an effective treatment for COVID19.
Lifescient will seek to enter into alliances and joint venture projects with pharmaceutical companies and other strategic partners to manufacture and supply effective drug(s) on a global basis.
Contact us if you wish to collaborate and jointly develop a therapeutic option for COVID-19 pandemic.